Literature DB >> 20176796

Concomitant enterotoxigenic Escherichia coli infection induces increased immune responses to Vibrio cholerae O1 antigens in patients with cholera in Bangladesh.

Fahima Chowdhury1, Yasmin A Begum, Mohammad Murshid Alam, Ashraful I Khan, Tanvir Ahmed, M Saruar Bhuiyan, Jason B Harris, Regina C LaRocque, Abu S G Faruque, Hubert Endtz, Edward T Ryan, Alejandro Cravioto, Ann-Mari Svennerholm, Stephen B Calderwood, Firdausi Qadri.   

Abstract

Vibrio cholerae O1 and enterotoxigenic Escherichia coli (ETEC) are major bacterial pathogens that cause dehydrating disease requiring hospitalization of children and adults. The cholera toxin (CT) produced by V. cholerae O1 and the heat-labile toxin (LT) and/or heat-stable toxin (ST) of ETEC are responsible for secretory diarrhea. We have observed that about 13% of hospitalized diarrheal patients are concomitantly infected with V. cholerae O1 and ETEC. In order to understand the outcome of such dual infections on the clinical and immunological responses in cholera patients, we studied patients infected with V. cholerae O1 (group VC; n = 25), those infected with both V. cholerae O1 and ETEC (group VCET; n = 25), and those infected with ETEC only (group ET; n = 25). The VCET group showed more severe dehydration and had a higher intake of intravenous fluid and more vomiting than the ETEC group (P = 0.01 to 0.003). The VCET patients showed higher vibriocidal responses and increased antibody titers to cholera toxin and lipopolysaccharide (LPS) in plasma than did the V. cholerae O1 patients (P = 0.02 to <0.001). All responses in the V. cholerae O1 and in the VCET groups were more robust than those seen in the group infected with ETEC only (P = 0.01 to <0.001). We thus show that concomitant colonization with ETEC induces immune responses to V. cholerae antigens that are more robust than those seen with V. cholerae O1 infection alone. It is possible that LT or other factors expressed by ETEC may play a role as a mucosal adjuvant in enhancing the immune responses to V. cholerae O1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20176796      PMCID: PMC2863502          DOI: 10.1128/IAI.01426-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization.

Authors:  M Vajdy; N Y Lycke
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

2.  Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay.

Authors:  A M Svennerholm; M Wikström; M Lindblad; J Holmgren
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

3.  The aetiology of diarrhoea in children at an urban hospital in Bangladesh.

Authors:  M Moyenuddin; K M Rahman; D A Sack
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

4.  Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin.

Authors:  C O Elson; W Ealding
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

5.  Role of cholera toxin in enteric colonization by Vibrio cholerae O1 in rabbits.

Authors:  N F Pierce; J B Kaper; J J Mekalanos; W C Cray
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

6.  Rotavirus and hemolytic enteropathogenic Escherichia coli in weanling diarrhea of pigs.

Authors:  J G Lecce; R K Balsbaugh; D A Clare; M W King
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

7.  Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.

Authors:  J D Clements; N M Hartzog; F L Lyon
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

8.  A two-year survey of the incidence of heat-labile enterotoxin-producing Escherichia coli and other enteric pathogens in travellers returning to the Sheffield area.

Authors:  P A Chapman; D L Mitchelmore
Journal:  Epidemiol Infect       Date:  1988-10       Impact factor: 2.451

9.  Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli.

Authors:  T K Sixma; S E Pronk; K H Kalk; E S Wartna; B A van Zanten; B Witholt; W G Hol
Journal:  Nature       Date:  1991-05-30       Impact factor: 49.962

10.  A two-year study of bacterial, viral, and parasitic agents associated with diarrhea in rural Bangladesh.

Authors:  R E Black; M H Merson; A S Rahman; M Yunus; A R Alim; I Huq; R H Yolken; G T Curlin
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

View more
  10 in total

1.  Frequency of reexposure to Vibrio cholerae O1 evaluated by subsequent vibriocidal titer rise after an episode of severe cholera in a highly endemic area in Bangladesh.

Authors:  Ana A Weil; Fahima Chowdhury; Ashraful I Khan; Daniel T Leung; Taher Uddin; Yasmin Ara Begum; Nirod Chandra Saha; Richelle C Charles; Regina C Larocque; Jason B Harris; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  Am J Trop Med Hyg       Date:  2012-09-10       Impact factor: 2.345

Review 2.  Cholera.

Authors:  Jason B Harris; Regina C LaRocque; Firdausi Qadri; Edward T Ryan; Stephen B Calderwood
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

Review 3.  Immune responses to cholera in children.

Authors:  Daniel T Leung; Fahima Chowdhury; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Expert Rev Anti Infect Ther       Date:  2012-04       Impact factor: 5.091

4.  Molecular characterization of enterotoxigenic Escherichia coli isolates recovered from children with diarrhea during a 4-year period (2007 to 2010) in Bolivia.

Authors:  Lucia Gonzales; Samanta Sanchez; Silvia Zambrana; Volga Iñiguez; Gudrun Wiklund; Ann-Mari Svennerholm; Asa Sjöling
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

5.  Utility of multiplex  polymerase chain reaction (PCR) in diarrhea-An Indian perspective.

Authors:  Balavinoth Ramakrishnan; Ram Gopalakrishnan; P Senthur Nambi; Suresh Kumar Durairajan; R Madhumitha; Anil Tarigopula; Chitra Chandran; V Ramasubramanian
Journal:  Indian J Gastroenterol       Date:  2018-09-22

6.  Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.

Authors:  A A Tarique; A Kalsy; M Arifuzzaman; S M Rollins; R C Charles; D T Leung; J B Harris; R C Larocque; A Sheikh; M S Bhuiyan; R Saksena; J D Clements; S B Calderwood; F Qadri; P Kovác; E T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-02-22

7.  High quality reference genomes for toxigenic and non-toxigenic Vibrio cholerae serogroup O139.

Authors:  Matthew J Dorman; Daryl Domman; Muhammad Ikhtear Uddin; Salma Sharmin; Mokibul Hassan Afrad; Yasmin Ara Begum; Firdausi Qadri; Nicholas R Thomson
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

8.  Assessment of disease specific immune responses in enteric diseases using dried blood spot (DBS).

Authors:  Md Saruar Bhuiyan; Motaher Hossain; Salma Sharmin; Afsana Shirin; Farhana Khanam; Fahima Chowdhury; Afroza Akter; Ashraful Islam Khan; Muhammad Ikhtear Uddin; Taufiqur Rahman Bhuiyan; Firdausi Qadri
Journal:  PLoS One       Date:  2019-06-17       Impact factor: 3.240

9.  The history, genome and biology of NCTC 30: a non-pandemic Vibrio cholerae isolate from World War One.

Authors:  Matthew J Dorman; Leanne Kane; Daryl Domman; Jake D Turnbull; Claire Cormie; Mohammed-Abbas Fazal; David A Goulding; Julie E Russell; Sarah Alexander; Nicholas R Thomson
Journal:  Proc Biol Sci       Date:  2019-04-10       Impact factor: 5.349

Review 10.  Elucidating Host-Pathogen Interactions Based on Post-Translational Modifications Using Proteomics Approaches.

Authors:  Vaishnavi Ravikumar; Carsten Jers; Ivan Mijakovic
Journal:  Front Microbiol       Date:  2015-11-20       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.